



Published in final edited form as:

Pediatr Infect Dis J. 2015 March ; 34(3): e52–e57. doi:10.1097/INF.0000000000000578.

Syphilis in HIV-Infected Mothers and Infants: Results from the NICHD/HPTN 040 Study

Nava Yeganeh, MD, MPH¹, Heather D. Watts, MD², Margaret Camarca, MPH³, Gabriel Soares¹, Esau Joao, MD⁴, Jose Henrique Pilotto, MD⁵, Glenda Gray, MD⁶, Gerhard Theron, MD⁷, Breno Santos, MD⁸, Rosana Fonseca, MD⁹, Regis Kreitchmann, MD¹⁰, Jorge Pinto, MD¹¹, Marisa Mussi-Pinhata, MD¹², Mariana Ceriotto, MD¹³, Daisy Maria Machado¹⁴, Valdilea G. Veloso, MD¹⁵, Beatriz Grinzstejn, MD¹⁵, Mariza G Morgado¹⁵, Yvonne Bryson, MD¹, Lynne M. Mofenson, MD², Karin Nielsen-Saines, MD MPH¹, and on behalf of the NICHD HPTN 040/P1043 Study Team

¹ David Geffen UCLA School of Medicine, Los Angeles, CA

² Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD

³ Westat, Rockville, MD

⁴ Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil

⁵ Hospital Geral de Nova Iguaçu, Nova Iguaçu and Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, (Fiocruz), Rio de Janeiro, Brazil

⁶ Perinatal HIV Research Unit, University of Witwatersrand/Chris Hani Baragwanath Hospital, Johannesburg, South Africa

⁷ Stellenbosch University/Tygerberg Hospital, Cape Town, South Africa

⁸ Hospital Conceicao, Porto Alegre, RS, Brazil

⁹ Hospital Femina, Porto Alegre, RS, Brazil

¹⁰ Irmandade da Santa Casa de Misericórdia de Porto Alegre, RS, Brazil

¹¹ Federal University of Minas Gerais, Belo Horizonte, MG, Brazil

¹² Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil

¹³ Foundation for Maternal and Infant Health (FUNDASAMIN), Buenos Aires, Argentina

¹⁴ Escola Paulista de Medicina-Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil

¹⁵ Laboratório de Pesquisa Clínica em DST e AIDS - Instituto de Pesquisa Clínica Evandro Chagas - Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.

Correspondence/Address for Reprints: Nava Yeganeh MD, MPH, Dept of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States. Division of Infectious Disease-MDCC 22-442 10833 Le Conte Ave, Los Angeles, CA 90095. Telephone 310 825-5235. Fax 310-206-4764, nyeganeh@mednet.ucla.edu.

Financial Disclosure: Authors have no other relevant financial disclosures.

Conflict of Interest: Authors do not have any conflicts of interest to disclose.

Abstract

Background—Untreated syphilis during pregnancy is associated with spontaneous abortion, stillbirth, prematurity and infant mortality. Syphilis may facilitate HIV transmission, which is especially concerning in low and middle income countries where both diseases are common.

Methods—We performed an analysis of data available from NICHD/HPTN 040 (P1043), a study focused on the prevention of *intrapartum* HIV transmission to 1684 infants born to 1664 untreated HIV-infected women. The present analysis evaluates risk factors and outcomes associated with a syphilis diagnosis in this cohort of HIV-infected women and their infants.

Results—Approximately 10% (n=171) of women enrolled had serological evidence of syphilis without adequate treatment documented and 1.4% (n=24) infants were dually HIV and syphilis infected. Multivariate logistic analysis showed that compared to HIV-infected women, co-infected women were significantly more likely to self-identify as non-white (AOR 2.5, 95% CI 1.5-4.2), to consume alcohol during pregnancy (AOR 1.5, 95% CI 1.1-2.1) and to transmit HIV to their infants (AOR 2.1, 95% CI 1.3-3.4), with 88% of HIV infections being acquired in-utero. As compared to HIV infected or HIV exposed infants, co-infected infants were significantly more likely to be born to mothers with VDRL titers $\geq 1:16$ (AOR 3, 95% CI 1.1-8.2) and higher viral loads (AOR 1.5, 95% CI 1.1-1.9). Of 6 newborns with symptomatic syphilis, 2 expired shortly after birth, and 2 were HIV-infected.

Conclusion—Syphilis continues to be a common co-infection in HIV-infected women and can facilitate *in utero* transmission of HIV to infants. Most infants are asymptomatic at birth, but those with symptoms have high mortality rates.

Keywords

HIV mother to child transmission; congenital syphilis; prenatal care

Congenital syphilis is a significant public health problem, affecting an estimated one million pregnancies per year throughout the world.¹ Pregnant women diagnosed with early stages of syphilis are at the highest risk for vertically transmitting syphilis to infants: 60-90% of pregnant women with untreated primary or secondary syphilis will transmit syphilis to their fetus as compared to less than 10% of women with late latent syphilis.² If not fatal, the bones, liver, pancreas, intestine, and kidneys of the fetus can be severely affected, and overt infection can manifest in the fetus, the newborn, or later in childhood.³ The diagnosis of congenital syphilis is complicated by the fact that more than two-thirds of neonates are asymptomatic at birth and treatment delay can lead to permanent damage and disability.⁴ Because of this, congenital syphilis is diagnosed presumptively based on the mother's reactive non-treponemal titer, reactive treponemal (confirmatory) testing and lack of adequate treatment with a penicillin regimen more than 4 weeks prior to delivery as defined by the Center for Disease Control Sexually Transmitted Diseases (CDC STD) guidelines.⁵

Congenital syphilis often occurs in areas with high HIV prevalence.⁶ Identifying potential risk factors and associated outcomes in women and infants infected with HIV and syphilis would benefit global efforts to eliminate both diseases in infants.^{7,8} The NICHD /HPTN 040 (P1043) was a study designed to prevent *intrapartum* HIV transmission to infants born to

untreated HIV-infected women.⁹ Formula-fed live infants born to 1664 mothers diagnosed with HIV during the time of labor and delivery were randomly assigned to one of three antiviral regimens. The study results demonstrated that a multi-drug infant regimen is superior to zidovudine alone in preventing primary HIV infection at 3 months in infants uninfected at birth.⁹ Prior observational studies have shown that concurrent syphilis infection leads to increased HIV mother-to-child transmission rates for reasons that are not completely understood.¹⁰⁻¹² However, there is a paucity of literature regarding perinatal HIV and syphilis dual exposure and early clinical outcomes in this population. In this analysis, we focused on identifying risk factors associated with maternal syphilis as well as factors associated with syphilis and HIV co-infection in infants enrolled in NICHD /HPTN 040 (P1043) in order better clarify the relationship between HIV and syphilis in this vulnerable population.

MATERIALS AND METHODS

We performed a secondary analysis of data collected in the NICHD /HPTN 040 (P1043) study⁹ which enrolled HIV-infected mothers who had not received antiretroviral therapy (ART) prior to labor. We excluded 11 mothers whose confirmatory testing was not consistent with HIV infection (false-positives). All mothers provided written informed consent. Enrollment occurred at 17 sites in Brazil, South Africa, Argentina and the United States. The study was approved by local and collaborating institutional review boards.

At study enrollment, all mothers were interviewed about risk behaviors including illegal substance use, alcohol use, tobacco use, as well as receipt of prior prenatal care. Maternal HIV RNA levels, T lymphocyte cell subsets, and Venereal Disease Research Laboratory (VDRL) titers were obtained at the time of labor/delivery. Confirmatory syphilis testing with Treponema Pallidum Particle Agglutination Assay (TPPA), Treponema Pallidum Particle Hemagglutination Assay (TPHA), or Fluorescent Treponemal Antibody-absorption (FTA-ABS) was conducted on women with positive VDRL results as per local standard of care. Infant data included birth weight, gestational age, HIV antiretroviral treatment arm, whether zidovudine (ZDV) was received during the *intrapartum* period by the mother, and if performed by the site, infant's VDRL titer. If infants were admitted for treatment of syphilis, this information was also recorded with a brief summary of their clinical course.

HIV Diagnosis

Infant HIV infection was diagnosed with two positive HIV DNA PCR results in blood specimens collected at birth, 10-14 days, 4-6 weeks, 3 months and 6 months. Infants with positive DNA PCR within 48 hours of birth and confirmatory results on repeat testing were classified as having *in utero* HIV infection. Infants with a negative result at birth and positive results on subsequent testing were classified as acquiring HIV infection through the *intrapartum* route. If the infant expired prior to receiving two virologic tests, the HIV status was listed as *unknown*. Ninety-seven (5%) infants discontinued the study before reaching the 3 month primary endpoint for HIV diagnosis for reasons including death (n=21), withdrawal of consent (n=37), loss to follow up (n=32), and relocation (n=7). While it is impossible to conclusively confirm or exclude HIV infection as these infants lacked confirmatory tests, of

the 97 infants with unknown HIV status, 2 had one positive HIV DNA assay before 3 months of age (the study endpoint) and 95 had one negative viral test also before 3 months of age. All infants were exclusively formula-fed to avoid post-partum transmission. These 97 infants were censored from our analysis in Table 2. All laboratory assays were performed by quality assured laboratories supported by the NICHD and the International Maternal Pediatric Adolescent AIDS Clinical Trials group.

Syphilis Diagnosis

For this analysis, current maternal infection with syphilis (presumably untreated, i.e., without treatment documentation) was defined as any reactive VDRL result with a reactive confirmatory test, or a reactive VDRL titer without a documented confirmatory test. Those with non-reactive confirmatory tests were considered to have false positive VDRL results and were excluded from further analysis. Congenital syphilis was considered in infants born to mothers who were diagnosed with current syphilis at the time of delivery or after birth without any evidence of treatment more than 4 weeks prior to delivery, per CDC guidelines scenario 2.⁵ Confirmed cases included infants who were diagnosed with syphilis based on abnormal physical exam, or a serum quantitative non-treponemal serologic titer that was fourfold higher than the mother's titer (CDC guidelines scenario 1).

In this secondary analysis, we employed a slightly different definition of syphilis than in the primary parent study in order to more closely follow CDC guidelines. In the initial published study, in the absence of confirmatory treponemal testing, higher maternal VDRL titers of 1:16 (n=19) were required for a case definition of congenital syphilis. However, since syphilis transmission can occur even with low maternal VDRL titers, we expanded the case definition to include all cases of untreated syphilis irrespective of the VDRL titers and added 20 extra case mothers to study cohort. Therefore, our final cohort in this analysis included 132 mothers with positive confirmatory testing for syphilis and 39 with presumed syphilis, but without confirmatory testing.

Statistical Analysis

Two-sample T-test and Pearson chi-square statistics were used to analyze continuous and categorical outcomes, respectively. Univariate and multivariate logistic regression was performed to assess predictors associated with positive syphilis results in mothers. Variables included in the multivariate model were age, ethnicity, tobacco use, illegal drug use, alcohol use, continent of origin, presence of prenatal care, CD4 T lymphocyte count and plasma log₁₀ HIV RNA levels. Univariate and multivariate logistic regression was performed to assess predictors associated with co-infection with HIV and congenital syphilis in infants. Covariates with a P value of less than 0.10 were included in the multivariate model comprised of birth weight, maternal VDRL titers, maternal HIV RNA log₁₀ viral load and whether patient was from South America or South Africa. All computations were done using STATA version 11.1. (Cary, NC).

RESULTS

We identified 182 pregnant women with reactive VDRL results among the 1664 newly diagnosed HIV-infected women enrolled in the study (Figure 1). Among these women, 132 had a reactive confirmatory treponemal test and 39 had no recorded confirmatory test result, totaling 171 women who were presumably co-infected with syphilis and HIV. Eleven women with a reactive VDRL had nonreactive confirmatory tests, and were presumed to have false positive VDRL titers (VDRL false positive rate of 8%). Of the 171 women with presumed untreated syphilis (serological evidence of infection without treatment documentation), 123 were from Brazilian sites, 46 were South African, and 2 were from Argentina. Prevalence rates of syphilis in this cohort of newly diagnosed HIV positive women ranged from 6% in Johannesburg to more than 17% in Cape Town, South Africa and Belo Horizonte, Brazil. (Figure in Supplemental Digital Content). A total of 144 women had documented referral for syphilis treatment in the postpartum period. The most common recorded reason for no treatment referral was past treatment (n=12), although none reported treatment during current gestation. Other common reasons for no treatment included low VDRL titer (n=6) and repeat negative results (n=5). However, we did not have documentation of negative result results and so these 5 individuals were included in our subsequent analyses.

Comparing the 171 HIV-infected women with serological evidence for syphilis to those who had negative serological testing (n=1439), those who were co-infected with syphilis and HIV were significantly more likely to be non-white (AOR 2.5, 95% CI 1.5-4.2), and to report drinking alcohol during pregnancy (AOR 1.5, 95% CI 1.1-2.3) (Table 1). There was a slight yet statistically significant difference in age between the two groups, with co-infected women having a mean age of 28 years (range of 15-44 years) as compared to a mean age of 27 years (range of 13-47 years) in women only infected with HIV. We did not see a significant difference in the amount of prenatal care between the two groups in our adjusted model, with a median of 4 visits in both groups. In this subanalysis, mothers co-infected with HIV and syphilis had twice the odds (AOR 2.1, 95% CI 1.3-2.4) of transmitting HIV infection to their babies. Of the 1684 infants born to 1664 mothers enrolled in the NICHD/HPTN 040 (P1043) trial, 24 (1.4%) were co-infected with HIV and syphilis, and of these infants, 21 (88%) acquired HIV infection in utero. Among the 116 infants infected with HIV whose mothers did not have serological evidence of untreated syphilis infection, 62% of them acquired HIV in-utero. (Table 1) Table 2 shows the results comparing infants who were co-infected with both HIV and congenital syphilis with the remaining HIV exposed/uninfected infants and HIV infected infants. Our multivariate logistic regression model showed that co-infected infants were more likely born to mothers with VDRL titers 1:16 (AOR 3, 95% CI 1.1-8.2), higher maternal viral loads (AOR 1.5, 95% CI 1.1-1.9) and were also significantly more likely to have lower birth weights, although this difference was not significant in the multivariate analysis. Exploratory analysis was done comparing co-infected babies to infants infected only with syphilis or HIV, and similarly revealed lower birth weight in co-infected babies, which was no longer significant in the multivariate model (data not shown).

Of these 173 infants born to 171 HIV-infected mothers with serologic evidence of untreated syphilis infection, 120 infants were recorded as being hospitalized to receive treatment for congenital syphilis. Six infants had physical examinations suggestive of “confirmed” congenital syphilis disease per CDC guidelines scenario. (Table in Supplemental Digital Content.) Two of the patients died prior to HIV diagnostic testing and two acquired HIV *in utero*. One infant had a rash on the extremities presumed to be secondary to syphilis although the mother's nontreponemal titer was initially non-reactive, which is suggestive of previously treated infection. However, this infant's VDRL result was positive at 1:4 and mother's subsequent testing performed within 10 days after giving birth was similarly positive. None of the infants had VDRL titers four-fold or greater than their mother's titers. All other infants who were treated for syphilis were asymptomatic.

DISCUSSION

Inadequately treated *T. pallidum* infection can result in transplacental infection of the fetus, causing perinatal death, prematurity, low birth weight, congenital anomalies and long term sequelae including deafness and neurological impairment.^{2,13-15} Since most infants are asymptomatic at birth, all infants born to untreated infected mothers should be presumptively evaluated for congenital syphilis by cerebral spinal fluid analysis for VDRL titers, cell count, and protein, a blood sample for a complete blood count with differential, and platelet count, and long-bone radiographs. Treatment with penicillin for up to 10 days should be considered.⁵ In the present analysis of the NICHD /HPTN 040 (P1043) cohort which included 1664 mothers diagnosed with HIV during the time of labor and delivery, 171 (10%) mothers were noted to have serological results suggestive of untreated syphilis infection. This is consistent with a review suggesting that 9.5% of all HIV-infected adults are co-infected with syphilis.¹⁶ Prior studies show that inadequate prenatal care appears to be the biggest contributor to delivering an infant with congenital syphilis, but the magnitude of VDRL titers,¹⁷⁻²⁰ gestational week of syphilis treatment,²¹ low maternal socioeconomic status,²² multiple sexual partners²² and maternal drug use¹⁸ could all contribute to this outcome. Our results are unique in that they focus specifically on an HIV infected population, but are similar to the above studies showing that alcohol use during pregnancy and non-white ethnicity are associated with HIV infected mothers being co-infected with syphilis. In both Brazil and South Africa, non-white ethnicity may act as a marker for social inequities and poor access to medical care as opposed to a biological “predisposition” to disease.²³ In our univariate analysis, the lack of prenatal care and illegal substance use were also associated with active syphilis infection. As these women had been diagnosed late in pregnancy with HIV infection and 38% had no prenatal care, they represent a highly vulnerable sub-population at great risk for poor outcomes. Even those women who received prenatal care (with a median of 4 prenatal visits in both infected and non-infected cohorts) were not diagnosed and treated for HIV and syphilis until enrollment into this study, which is an issue of great concern as diagnosis and treatment for syphilis is widely available and should be immediately offered during pregnancy. Of note, others have shown that a higher number of prenatal care visits corresponds with lower rates of congenital syphilis, but we did not see this trend in our analysis.¹⁸ Widespread use of rapid tests to accurately diagnose

these diseases combined with improved infrastructure and training of medical staff may help ameliorate this significant deficiency in health care systems.

Infants born to mothers infected with both untreated HIV and syphilis were more likely to have acquired HIV infection *in utero*, likely secondary to placental inflammation caused by syphilis infection.²⁴ Furthermore, syphilis, like many other acute infections, can increase HIV viral load and decrease CD4+ T lymphocyte cells, although we did not note this association in our study population.²⁵ In general, syphilis has been estimated to increase sexual HIV transmission rates 2- to 9-fold and HIV acquisition 2- to 4-fold,^{26, 27} consistent with our results. For this analysis, we used a broader definition of maternal syphilis infection as supplied by the CDC STD guidelines and included all mothers who had positive VDRL titers even if they did not have confirmatory testing performed, increasing the original syphilis cohort by 20 subjects. Using this definition, we did see a two-fold risk (AOR 2.1, 95% CI 1.3-2.4) of HIV acquisition in infants exposed to syphilis. Moreover, as VDRL titers are used to track disease activity, with elevated titers being associated with more severe infection, it is predictable that elevated VDRL titers would signal increased syphilitic disease activity and inflammation, thus augmenting the risk of HIV acquisition by infants. All other parameters evaluated in the present analysis including maternal zidovudine administration during delivery and infant and antiretroviral treatment arm had no effect in preventing co-infection. This is consistent with our study design since >85% of co-infected patients had acquired HIV *in utero*, prior to any intrapartum interventions.

Although we do not have follow up data on all infants including serial VDRL titers and physical exams, as this was not the main outcome of the parent study, we did notice that most infants (>95%) were asymptomatic of disease at birth and none had 4-fold or higher titers than their mothers. One case report suggests that HIV-exposed uninfected infants may have negative serological test for syphilis because of immunological dysregulation secondary to exposure to HIV antigens.²⁸ We also noted that one infant was diagnosed with congenital syphilis based on physical examination (Table 3 in Supplemental Digital Content, Patient 6); although mother's initial VDRL test was nonreactive. This false negative result could potentially represent a new syphilis infection where delivery occurred prior to mother developing antibodies as mother's repeat VDRL titer performed shortly after birth was 1:4. Furthermore, there have been reports of false negative serological tests in HIV-infected individuals secondary to immune dysregulation.²⁹⁻³¹ It is significant to note that of our six infants with symptomatic syphilitic disease, two died shortly after birth.

Our study's strength is that it comprises one of the only analyses looking at a large cohort of HIV-infected mothers and their HIV exposed/infected infants with high rates of untreated maternal syphilis because the women had not accessed prenatal care. One main study limitation is that the primary focus of the parent study was not syphilis outcomes, thus we do not have follow up syphilis evaluations for all infants unless they were hospitalized. Another potential weakness is that we may have included infants who were not infected with syphilis among those with probable congenital syphilis because the widely accepted case definition is solely based on maternal history of diagnosis, a common problem with most studies evaluating early congenital syphilis.³² We included 39 women who had positive VDRL results and no confirmatory testing. However, we performed an exploratory analysis

removing all 39 individuals with positive VDRL results who did not have any confirmatory testing from our cohort. Despite this exclusion, maternal syphilis infection continued to be significantly associated with mother-to-child HIV transmission (OR 2.2, 95CI 1.3-3.71).

In conclusion, this study demonstrates that co-infected infants with HIV and symptomatic syphilis face high rates of mortality. All pregnant women, especially those diagnosed with HIV, should be immediately screened for syphilis, and if co-infected, should receive appropriate therapy to avoid adverse outcomes including *in utero* HIV infection of the infant and fetal/neonatal death. Infants born to HIV and syphilis co-infected mothers should receive full evaluation for syphilis and appropriate antibiotic management to avoid complications associated with untreated infection including skeletal deformities, developmental delay, and organ damage.³¹

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Source: The NICHD HPTN 040 study was supported by NICHD Contract # HHSN267200800001C (NICHD Control # N01-HD-8-0001) and U01 AI047986 (Brazilian AIDS Prevention Trials International Network), NIAID/NIH. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632], the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Mental Health (NIMH) [AI068632]. In addition, the study was supported in part by Boehringer Ingelheim Pharmaceuticals Inc. (BIP), and GlaxoSmithKline on behalf of ViiV Healthcare. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and were fully responsible for all aspects of manuscript development. Boehringer-Ingelheim Pharmaceuticals, Inc and GlaxoSmithKline were given the opportunity to check the data used in the present manuscript for factual accuracy only. We thank the patients and their families who enrolled in this trial; and Marita McDonough and Lauren Petrella from Boehringer Ingelheim Pharmaceuticals and Helen Watson from GlaxoSmithKline (on behalf of ViiV Healthcare) for assistance with the donation of study drugs from their respective companies for the conduct of the study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The conclusions and opinions expressed in this article are those of the authors and do not necessarily reflect those of the National Institutes of Health or U.S. Department of Health and Human Services.

Acknowledgment of additional members of the NICHD/HPTN 040/PACTG 1043 protocol team: Argentina, Buenos Aires- Foundation for Maternal and Infant Health (FUNDASAMIN): Edgardo Szylid, Silvia Marzo. Brazil, Belo Horizonte- Federal University of Minas Gerais: Flavia Faleiro Ferreira, Fabiana Kakehasi. Porto Alegre- Hospital Nossa Senhora da Conceicao: Rita Lira. Porto Alegre-Hospital Femina: Carla Franceschini de Fraga Rita Lira. Porto Alegre-Irmandade da Santa Casa de Misericordia de Porto Alegre: Debora Fernandes Coelho, Alberto Sanseverino, Luis Carlos Ribeiro. Rio de Janeiro-Hospital dos Servidores do Estado: M. Leticia Santos Cruz, Ezequias Martins, Jacqueline Anita de Menezes, Luisa Andrea Torres Salgado. Rio de Janeiro- Hospital Geral de Nova Iguaçu: Ana Valeria Cordovil, Andréa Gouveia, Priscila Mazzucanti, Jorge Eurico Ribeiro. Rio de Janeiro- Laboratório de AIDS e Imunologia Molecular- Instituto Oswaldo Cruz- Fundação Oswaldo Cruz: Marisa G. Morgado. Sao Paulo-Universidade de Sao Paulo: Geraldo Duarte, Adriana Aparecida Tiraboschi Barbaro, Carolina Sales Vieira. Sao Paulo- Universidade Federal de Sao Paulo: Regina Succi. South Africa, Cape Town-Stellenbosch University and Tygerberg Hospital: Mark Cotton, Jeanne Louw, Elke Maritz. Johannesburg-Perinatal HIV Research Unit, University of Witwatersrand and Chris Hani Baragwanath Hospital: Sarita Lalsab, Shini Legoete, James Alasdair McIntyre, Mandisa Nyati. United States, Baltimore-Johns Hopkins University: Allison Agwu, Jean Anderson, Joan Bess, Jonathan Ellen, Todd Noletto, Nancy Hutton. Boston- Boston University School of Medicine: Mark Mirochnick. Gainesville-Shands Hospital: Carol Delany, Robert M. Lawrence. Jacksonville-University of Florida: Chas Griggs, Mobeen Rathore, Kathleen Thoma, Michelle Tucker. Long Beach- Miller Childrens Hospital: Audra Deveikis, Susan Marks. Newark-University Medical and Dental School of NJ: Linda Bettica, James M. Oleske. San Juan City-San Juan City Hospital: Midnela Acevedo Flores, Elvia Pérez. Davis- University of California at Davis: Ruth Dickover. Los Angeles-University of California Los Angeles: Bonnie Ank, Oswaldo Cruz Foundation, Rio de Janeiro (FIOCRUZ): Francisco Inacio Bastos, Ronaldo Ismerio Moreira, Marília Santini de Oliveira, Monica Derrico, Valéria Ribeiro, Thiago Torres e FIOTEC (Fundação para o Desenvolvimento Científico e Tecnológico). Westat, Inc.: Emmanuel Aluko, James Bethel, Yolanda Bertucci, Jennifer Bryant, Patty Chen,

Barbara Driver, Ruby Duston, Adriana Ferreira, Priya Guyadeen, Sarah Howell, Marsha Johnson, Linda Kaufman, Naomi Leshabane, Lilya Meyerson, Rita Patel, Lubima Petrova, Georgine Price, Susan Raitt, Scott Watson, Yiling Xu, Eunice Yu. Other protocol team members included George Siberry, Jack Moye, and Jennifer Read from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Elizabeth Smith and Sheryl Zwierski from the National Institute of Allergy and Infectious Diseases (NIAID).

REFERENCES

1. Walker DG, Walker GJ. Prevention of congenital syphilis--time for action. *Bulletin of the World Health Organization*. 2004; 82:401. [PubMed: 15356930]
2. Fiumara N, Fleming W, Downing J. The incidence of prenatal syphilis at the Boston City Hospital. *New England Journal of Medicine*. 1952; 247:48–52. [PubMed: 14941281]
3. Christian CW, Lavelle J, Bell LM. Preschoolers with syphilis. *Pediatrics*. 1999; 103:E4. [PubMed: 9917484]
4. Ortiz-Lopez N, Diez M, Diaz O, Simon F, Diaz A. Epidemiological surveillance of congenital syphilis in Spain, 2000-2010. *The Pediatric infectious disease journal*. 2012; 31:988–990. [PubMed: 22572752]
5. Workowski KA, Berman S, Centers for Disease C. Prevention. Sexually transmitted diseases treatment guidelines, 2010. *MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control*. 2010; 59:1–110.
6. Woods CR. Syphilis in children: congenital and acquired. *Seminars in pediatric infectious diseases*. 2005; 16:245–257. [PubMed: 16210105]
7. WHO: Department of Reproductive Health and Research. Investment case for eliminating mother-to-child transmission of syphilis: Promoting better maternal and child health and stronger health systems. Geneva, Switzerland: 2012.
8. UNAIDS. *Global Plan Towards the Elimination of New HIV Infections among Children by 2015 and Keeping their Mother's Alive*. United Nations; NY, NY: 2011.
9. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *The New England journal of medicine*. 2012; 366:2368–2379. [PubMed: 22716975]
10. Lee MJ, Hallmark RJ, Frenkel LM, Del Priore G. Maternal syphilis and vertical perinatal transmission of human immunodeficiency virus type-1 infection. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 1998; 63:247–252.
11. Mwapasa V, Rogerson SJ, Kwiek JJ, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. *Aids*. 2006; 20:1869–1877. [PubMed: 16954728]
12. Chibwasha CJ, Giganti MJ, Putta N, et al. Optimal time on HAART for prevention of mother-to-child transmission of HIV. *Journal of acquired immune deficiency syndromes*. 2011; 58:224–228. [PubMed: 21709566]
13. Ricci JM, Fojaco RM, O'Sullivan MJ. Congenital syphilis: the University of Miami/Jackson Memorial Medical Center experience, 1986-1988. *Obstetrics and gynecology*. 1989; 74:687–693. [PubMed: 2812644]
14. Watson-Jones D, Chungalucha J, Gumodoka B, et al. Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. *The Journal of infectious diseases*. 2002; 186:940–947. [PubMed: 12232834]
15. Newman L, Kamb M, Hawkes S, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. *PLoS medicine*. 2013; 10:e1001396. [PubMed: 23468598]
16. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. *Sexually transmitted infections*. 2011; 87:183–190. [PubMed: 21330572]
17. Southwick KL, Blanco S, Santander A, et al. Maternal and congenital syphilis in Bolivia, 1996: prevalence and risk factors. *Bulletin of the World Health Organization*. 2001; 79:33–42. [PubMed: 11217665]

18. Webber MP, Lambert G, Bateman DA, Hauser WA. Maternal risk factors for congenital syphilis: a case-control study. *American journal of epidemiology*. 1993; 137:415–422. [PubMed: 8460624]
19. McFarlin BL, Bottoms SF, Dock BS, Isada NB. Epidemic syphilis: maternal factors associated with congenital infection. *American journal of obstetrics and gynecology*. 1994; 170:535–540. [PubMed: 8116709]
20. Qin JB, Feng TJ, Yang TB, et al. Risk factors for congenital syphilis and adverse pregnancy outcomes in offspring of women with syphilis in Shenzhen, China: a prospective nested case-control study. *Sexually transmitted diseases*. 2014; 41:13–23. [PubMed: 24326577]
21. Liu JB, Hong FC, Pan P, et al. A risk model for congenital syphilis in infants born to mothers with syphilis treated in gestation: a prospective cohort study. *Sexually transmitted infections*. 2010; 86:292–296. [PubMed: 20460262]
22. Lago EG, Rodrigues LC, Fiori RM, Stein AT. Congenital syphilis: identification of two distinct profiles of maternal characteristics associated with risk. *Sexually transmitted diseases*. 2004; 31:33–37. [PubMed: 14695956]
23. Burgard S. Race and pregnancy-related care in Brazil and South Africa. *Social science & medicine*. 2004; 59:1127–1146. [PubMed: 15210086]
24. Sheffield JS, Sanchez PJ, Wendel GD Jr. et al. Placental histopathology of congenital syphilis. *Obstet Gynecol*. 2002; 100:126–133. [PubMed: 12100814]
25. Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. *Aids*. 2004; 18:2075–2079. [PubMed: 15577629]
26. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *The New England journal of medicine*. 2000; 342:921–929. [PubMed: 10738050]
27. Palacios R, Jimenez-Onate F, Aguilar M, et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. *Journal of acquired immune deficiency syndromes*. 2007; 44:356–359. [PubMed: 17159654]
28. van Toorn R, Schoeman JF, Cotton M, Rabie H. Atypical features of congenital syphilis in an HIV-exposed uninfected neonate. *Pediatrics international : official journal of the Japan Pediatric Society*. 2010; 52:332–333. [PubMed: 20500488]
29. Kingston AA, Vujevich J, Shapiro M, et al. Seronegative secondary syphilis in 2 patients coinfecting with human immunodeficiency virus. *Archives of dermatology*. 2005; 141:431–433. [PubMed: 15837859]
30. Tikjob G, Russel M, Petersen CS, Gerstoft J, Kobayasi T. Seronegative secondary syphilis in a patient with AIDS: identification of *Treponema pallidum* in biopsy specimen. *Journal of the American Academy of Dermatology*. 1991; 24:506–508. [PubMed: 2061457]
31. Feigin, RD.; Cherry, J.; Kaplan, SL.; Demmler-Harrison, GJ., editors. *Feigin and Cherry's Textbook of Pediatric Infectious Diseases*. 6th edition.. Saunders; Philadelphia, PA: 2009.
32. Centers for Disease C. Prevention. Congenital syphilis - United States, 2003-2008. *MMWR. Morbidity and mortality weekly report*. 2010; 59:413–417. [PubMed: 20395934]




Figure 1. Algorithm describing HIV infected mothers with positive syphilis serology. Boxes shaded in grey were not included in the subanalysis. (VDRL: Venereal Disease Research Laboratory, HIV: Human Immunodeficiency Virus)

Table 1

Factors associated with confirmed or presumed syphilis in HIV infected mothers and HIV transmission to infant

	Syphilis N=171	No syphilis N=1493	Odds ratio (95% CI)	Adjusted Odds ratio (95% CI) ^a
Age (mean, SD)	28 (±6.3)	27 (±6.3)	1.03 (1-1.1) *	1.03 (1-1.06) *
Ethnicity (non-white)	153 (89%)	1166 (78%)	2.4 (1.4-3.9) *	2.5 (1.5-4.2) *
Illegal substance use (yes)	24 (14%)	123 (8%)	1.8 (1.1-2.9) *	1.5 (0.88-2.7)
Alcohol use (yes)	79 (47%)	511 (35%)	1.6 (1.2-2.3) *	1.5 (1.1-2.1) *
Tobacco use (yes)	61 (36%)	472 (32%)	1.2 (0.87-1.7)	1 (0.67-1.5)
CD4 count (cells/mm ³ , SD)	506 (±300)	516 (±310)	1	1
Log ₁₀ viral load (copies/ml, SD)	9.61 (±2)	9.5 (±1.9)	1.04 (0.96-1.1)	1.01 (0.93-1.1)
Gestational age at delivery (mean, SD)	38.5 (±1.7)	38.6 (±1.7)	0.96 (0.87-1)	1
No prenatal Care	76 (45%)	554 (37%)	1.4 (1-2) *	1.5 (0.9-2.12)
Region- (South Africa)	46 (27%)	420 (28%)	0.9 (0.63-1.3)	0.68 (0.44-1)
HIV transmitted to infant	24 (14%)	116 (8%)	2 (1.2-3.2) *	2.1 (1.3-3.4) *
HIV transmitted in utero n (% of total HIV cases)	21 (88%)	72 (62%)	4.3 (1.2-15.2) *	

SD: Standard Deviation, HIV: Human Immunodeficiency Virus

^a Adjusted for age, ethnicity, tobacco use, illegal drug use, alcohol use, continent of origin, presence of prenatal care, CD4 count and viral load

* P<0.05

Table 2

Risk factors associated with infant syphilis and HIV co-infection

	Co-infected infants with HIV & syphilis (n=24)	Infants not co-infected (n=1660)	Odds ratio (95% CI)	Adjusted odds ratio (95% CI) ^a
Birth weight (mean, SD)	2.735 kg (±430g)	2.991 kg (±522g)	0.99 (0.99-.1) *	1 (0.998-1)
Gestational wk (mean, SD)	38.3 (±2)	38.6 (±1.7)	0.88 (0.71-1.1)	
Maternal VDRL Titers [#]			3.7 (1.5-9.1) *	3 (1.1-8.2) *
1:1-1:8	12 (52%)	117 (80%)		
1:16	11 (48%)	29 (20%)		
Maternal log ₁₀ viral load (copies/ml, SD)	10.8 (±1.6)	9.5 (±2)	1.5 (1.2-1.9) *	1.5 (1.1-1.9) *
HIV Treatment arm			1 (0.44-2.4)	
Zidovudine only	8 (33%)	557 (34 %)		
Two and three drug group	16 (67%)	1103 (66%)		
Delivery type-vaginal	11 (46%)	1073 (65%)	0.45 (0.2-1)	
No use of zidovudine during delivery	12 (50%)	980 (59%)	0.69 (0.3-1.5)	
Region- Born in South Africa	3 (13%)	472 (28%)	0.36 (0.11-1.2)	0.3 (0.07-1.1)
Mothers not referred for syphilis treatment during L&D admission	2 (8%)	25 (17%)	.44 (0.1-2)	

SD: Standard Deviation, HIV Human Immunodeficiency Virus, VDRL: Venereal Disease Research Laboratory, L&D: Labor and Delivery

[#] 3 unknown titer levels

* P value <0.05

^a Adjusted for birthweight, maternal VDRL titers, maternal log₁₀ viral load, region